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Reactive oxygen speciesThe aim of this study was to demonstrate the safety and efﬁcacy of H2-saline infusion for treatment of rheumatoid
arthritis (RA). We conducted a randomized, double-blind, placebo-controlled investigation of the infusion of
1 ppmH2-dissolved saline (H2-saline) in 24 RA patients. Patients were randomized 1:1 to receive 500ml of either
H2-saline or placebo-saline,whichwas drop infused intravenously (DIV) daily for 5 days. The disease activity score
in 28 joints (DAS28) was measured at baseline, immediately post infusion, and after 4 weeks. Therapeutic effects
of H2-saline on joint inﬂammation were estimated bymeasuring serum biomarkers for RA, tumor necrosis factor-
α (TNFα), interleukin-6 (IL-6), matrix metalloproteinase-3 (MMP-3), and urinary 8-hydroxydeoxyguanosine
(8-OHdG). In the H2-infused group, average DAS28 decreased from 5.18 ± 1.16 to 4.02 ± 1.25 immediately
post infusion and reached 3.74±1.22 after 4 weeks. No signiﬁcant decrease inDAS28was observed in the placebo
group throughout the study. IL-6 levels in the H2 group signiﬁcantly decreased in 4 weeks by 37.3 ± 62.0%
compared to baseline, whereas it increased by 33.6± 34.4% in the placebo group. TNFα levels did not change re-
markably in the H2 or placebo groups in 4 weeks post-infusion compared to baseline. The relative ratio of 8-OHdG
in the H2 group also signiﬁcantly decreased by 4.7%. After 4 weeks, MMP3 was signiﬁcantly reduced by 19.2% ±
24.6% in the H2 group, and increased by 16.9% ± 50.2% in the placebo group. Drop infusion of H2 safely and
effectively reduced RA disease activity.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Rheumatoid arthritis (RA) is a chronic inﬂammatory disease that
affects approximately 1% of the population. RA is characterized by
irreversible joint damage accompanied by destruction of bone and car-
tilage. In addition, the chronic inﬂammation associated with RA often
damages the skin, subcutaneous tissue, and lungs.Moreover, inﬂamma-
tory reactions in the arterial endothelium, which occur independently
of atherosclerosis risk, promote endothelial dysfunction and increase
the risk of cardiovascular disease, thereby diminishing quality of life
and survival time [1,2]. Although the etiology is unknown, RA ishibashi), b_sato@e-miz.co.jp
kai@haradoi-hospital.com
i-hospital.com (Y. Naritomi),
ospital.com (H. Hara),
. This is an open access article undercertainly associated with autoimmune disorders, and its pathogenesis
has beenwell investigated. Auto-reactive T cells that inﬁltrate the syno-
vial tissue promote the immune response and lead to overproduction of
pro-inﬂammatory cytokines, such as tumor necrosis factor-α (TNFα)
and interleukin-6 (IL-6). Thus, early RA therapy is based on aggressive
biologic modiﬁcation of the disease through controlling synovial T
cells and/or suppressing the levels of cytokines implicated in the disease
[3,4]. In addition to these immunogenic factors, reactive oxygen species
(ROS) are also important therapeutic targets because they are upstream
of the cytokine-mediated inﬂammatory cascades. Activation of nuclear
factor (NF)-κB by excess ROS production leads to increased production
of pro-inﬂammatory cytokines, thereby creating a positive feedback
loop and promoting sustained RA inﬂammation [5]. Hydroxyl radicals,
a particular ROS, are harmful because of their rapid and indiscriminate
reactivity, and they are thought to play a certain role in the pathogenesis
of RA [6–8]. Therefore, clinically effective scavengers that can remove
ROS, including hydroxyl radicals, which are surplus to physiological or
biological requirements, are expected to emerge as therapeutic agents.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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with molecular hydrogen (H2) through transfer of an electron [9,10].
On the other hand, before being recognized as a medical gas, H2 has
long been used to prevent decompression gas emboli caused by the for-
mation of N2 bubbles during deep sea diving; therefore, the safety of H2
has beenpreviously established [11–13]. In contrast to general drugs, no
harmful effects of H2 are observed, even at high concentrations. The po-
tential role of H2 as an ROS scavenger was ﬁrst demonstrated by Gharib
et al. using a mouse model of schistosomiasis infection-induced chronic
liver inﬂammation [9]. Then, the therapeutic potential of H2 gas and H2-
enriched water was demonstrated in a rat model of reperfusion injury
[14]. In this previous study, it was demonstrated that H2 scavenges
peroxynitrite as well as hydroxyl radicals in cultured cells and in cell-
free experiments. Since then, numerous studies concerning the thera-
peutic potential of H2 against various diseases related to ROS have
been published [10,15]. Recently, we reported that H2 has therapeutic
potential for treatment of RA [16]. In the study, RA patients drank
500 ml of water containing approximately 5 ppm H2 (high H2 water)
daily for 8 weeks. Oxidative stress was effectively reduced, and RA dis-
ease activity was signiﬁcantly improved. The H2 absorbed from the
water was effective to complement conventional RA therapy, especially
in patients in early stages of disease progression or among patients neg-
ative for antibodies against cyclic citrullinated peptides (ACPA). Howev-
er, it is not currently clear how to effectively expose the joints with
synovitis or the circulating immune-related cells, which are responsible
for the chronic inﬂammation of RA, to H2. Moreover, it is not known
whether intake of high H2 water, by which H2 is thought to passively
diffuse through the stomach, is the most effective method for adminis-
tering H2. Additional methods for H2 intake should be investigated, es-
pecially as it has the potential to be a rapid, powerful, and safe anti-
inﬂammatory therapeutic strategy. One of the methods for H2 adminis-
tration is drop infusion of H2-dissolved saline (H2-saline). The aim of
this study was to demonstrate the therapeutic potential and safety of
H2-saline for treatment of RA.
2. Materials and methods
2.1. Patients and study design
We conducted a randomized, double-blind, placebo-controlled in-
vestigation, and 26 patients who fulﬁlled the 2010 American College
of Rheumatology criteria for RA were enrolled. To verify the safety of
intravenous H2-saline infusion and to conﬁrm the absence of acute infu-
sion reactions and allergic reactions, which may be masked in patients
with an inﬂammatory disease, 20 healthy volunteers were also enrolled
from June 2011. All patients and volunteers gave their informed consent
to enroll in the study, and this study was approved by the Haradoi
Hospital Ethics Committee.
To prepare the H2-saline, 250ml of saline in a soft bag was placed in
a water bath in which water circulates continuously so as to contain
1.6 ppm H2 generated by an electrolysis instrument (non-destructive
hydrogen-adding apparatus, MiZ Company, Fujisawa, Yokohama,
Japan); approximately 1 ppm H2 was dissolved in the saline before the
infusion. Details describing the concentration of H2 in the saline as
generated by the instrument are described elsewhere [17,18], and we
also conﬁrmed the concentration by using the methylene blue-
platinum colloid regent-based titration method [19]. Placebo-saline
was prepared in the same water bath without H2. Patients were ran-
domized 1:1 to receive 500 ml of either H2-saline (12 patients) or
placebo-saline (12 patients) administered by intravenous drop infusion
(DIV) before meal in the morning every day for 5 days. Infusion of each
250 ml bag took approximately 20 min, and the total DIV took approx-
imately 40 min.
The disease activity score 28 (DAS28) based on C-reactive protein
(CRP) levels is an estimation of clinical response that is measured by
changes in the disease activity score in 28 joints, using C-reactiveprotein levels [20]. DAS28 levels were estimated about 30 min before
starting the ﬁrst DIV (baseline level), immediately post-infusion (on
the 6th–8th day after the baseline), and in 4 weeks from baseline. In ad-
dition, fasting blood and urine samples were collected at each point.
DAS28 results were classiﬁed as good (DAS28 N 1.2), moderate
(0.6 b DAS28 ≤ 1.2), or no response (DAS28 ≤ 0.6), according to the
European League Against Rheumatism response criteria.
With regard to the safety study, 20healthy volunteerswere random-
ized 1:1 to the H2 group (mean age: 53.9 years [range, 28–84]) or place-
bo group (mean age: 51.8 years [range, 25–93]). They were infused
with 500 ml of saline with or without H2 every day for 3 days. All of
the conditions for the solution preparations were the same as the RA
study. The inﬂuences of H2-saline on the healthy volunteers were deter-
mined by general symptoms or complaints, and blood samples were
collected at baseline and 1 week following baseline.
2.2. Biochemical analysis
Serum levels of matrix metalloproteinase-3 (MMP3) were assayed
by the latex coagulating nephelometry method using anti-human
MMP-3 mouse monoclonal antibody at Mitsubishi Chemical Medience
Inc. (Tokyo, Japan). ACPA levels in serum and urinary 8-OHdG in RA
patients were estimated by ELISA using MESACUP-2 test CCP (cyclic
citrullinated peptides) and the New 8-OHdG Check ELISA kit, respec-
tively, atMitsubishi ChemicalMedience Inc. (Tokyo, Japan). Serum cyto-
kines, TNFα and IL-6, were measured using Millipore's MILLIPLEX
Human Cytokine kit by Filgen Inc. (Nagoya, Japan).
2.3. Statistical analyses
Data are presented as the mean ± standard deviation. Analysis of
variance was used to compare changes in variables between the
H2-saline and placebo-saline groups. The DAS28 scores at baseline, im-
mediately post-infusion, and in 4 weeks post-infusion were analyzed.
The signiﬁcance of differences in variables (IL-6, TNFα, MMP3, and
CRP levels) immediately post-infusion or in 4 weeks from baseline
was determined as a ratio of the value at each point to the baseline
value. Statistical signiﬁcance was set at p b 0.05. All analyses were
performed using SAS v9.3 (SAS Institute Inc., Cary, NC, USA).
3. Results
3.1. Patient characteristics
All of the data from the 20 healthy volunteers were within standard
values, and no patients in either the H2 or placebo group complained of
any adverse effects or changes in general conditions, including ﬂushing,
nausea, bradycardia, tachycardia, hyper- or hypotension, pale, dizziness,
diarrhea, pain, and general discomfort. No acute infusion reactions or
allergic reactions, which could be masked in case of inﬂammatory
diseases like RA, were observed. The biochemical and blood cell data
are shown in Table 1.
Among the RA patients, 2 patients who were randomized to receive
placebo-saline withdrew from the study in the ﬁrst 5 days (day 3); 1
withdrew for a personal reason, and the other preferred oral adminis-
tration. The remaining 24 patients (4 males, 20 females; mean age:
65 years [range, 26–85]) completed the study. The demographic data
for RA patients at baseline are shown in Table 2.
ACPA, a part of the EULAR classiﬁcation criteria for RA [21], were
found in 6 patients in the H2 group and 4 patients in the placebo
group. The median disease duration was 4 years and 7 months (range,
6 months to 13 years), and 3 patients in each group had early RA (dis-
ease duration b 12 months). None of the patients with early RA had re-
ceived any medication prior to the study. Five patients in the H2 group
and 4 patients in the placebo group with disease duration N12 months
also had not received any medication prior to the study. Three patients
Table 1
Biochemical and blood cell data from healthy volunteers.
Placebo (n = 10) H2 (n = 10)
Baseline 1 week Baseline 1 week
TP, g/dl 7.15 ± 0.367 7.68 ± 0.383 7.15 ± 0.577 7.48 ± 0.299
ALB, g/dl 4.29 ± 0.284 7.75 ± 0.150 4.13 ± 0.393 4.50 ± 0.141
LD, IU/l 151 ± 30.8 142 ± 18.1 161 ± 23.89 153 ± 9.93
AST, IU/l 20.0 ± 2.79 22.8 ± 3.70 21.1 ± 5.32 19.2 ± 1.60
ALT, IU/l 16.5 ± 4.65 21.3 ± 2.49 16.0 ± 5.93 14.4 ± 3.38
ALP, IU/l 185 ± 28.9 205 ± 25.1 195 ± 26.3 205 ± 22.8
GGT, IU/l 22.6 ± 7.61 23.0 ± 5.52 22.0 ± 10.4 18.8 ± 8.28
CK, IU/l 106 ± 44.8 115 ± 33.6 116 ± 62.2 117 ± 43.7
BUN, mg/dl 13.1 ± 4.20 14.3 ± 3.37 13.5 ± 2.52 12.6 ± 2.39
Cr, mg/dl 0.79 ± 0.18 0.78 ± 0.11 0.83 ± 0.15 0.88 ± 0.098
UA, mg/dl 5.29 ± 0.986 4.68 ± 0.59 5.47 ± 0.713 5.14 ± 0.136
TBL, mg/dl 0.77 ± 0.14 0.90 ± 0.16 0.76 ± 0.22 0.76 ± 0.14
ALD, IU/l 3.42 ± 0.722 3.86 ± 0.307 2.90 ± 0.671 2.85 ± 0.541
GLU, mg/dl 97.4 ± 10.1 95.0 ± 6.50 92.05 ± 8.11 94.00 ± 7.00
WBC, cells/ml 5640 ± 1360 4420 ± 1460 5270 ± 1030 4730 ± 477
RBC, ×104 cells/ml 491 ± 45.8 513 ± 49.0 450 ± 64.2 482 ± 33.4
Hb, g/dl 14.7 ± 1.26 15.1 ± 1.29 14.0 ± 1.91 14.1 ± 2.01
CRP, mg/dl 0.06 ± 0.037 0.08 ± 0.043 0.10 ± 0.095 0.07 ± 0.030
Data are presented as themean ± standard deviation. No statistically signiﬁcant changes
were observed between baseline and 1 week post-infusion in either placebo or H2 group.
TP, total protein; ALB, albumin; LD, lactate dehydrogenase; AST, aspartate aminotransfer-
ase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; GGT, gamma-glutamyl
transpeptidase; CK, creatine kinase; BUN, blood urea nitrogen; Cr, creatinine; UA, uric
acid; TBL, total bilirubin; ALD, aldolase; GLU, glucose; WBC, white blood cell; RBC, red
blood cell; Hb, hemoglobin; CRP, C-reactive protein.
Fig. 1. a. Disease activity scores in 28 joints (DAS28) at baseline, immediately post-infusion, and
in4weeks (4w). Error bars represent themeanand standarddeviation formeasurements in12
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in the H2 group and 2 patients in the placebo group had been treated
with bucillamine and glucocorticoid, respectively. None of the 24 pa-
tients started additional disease-modifying anti-rheumatic drugs
(DMARDs) and/or biological drugs during the study.patients in the H2-infused group (closed circles) or 12 patients in the placebo group (closed
triangles). b. The difference in DAS28 from baseline to immediately post-infusion or in 4
weeks. There were 6 patients positive for antibodies against cyclic citrullinated peptides
(ACPA) (black columns) in the H2-infused group and 4 ACPA-positive patients in the placebo
group. There were 6 ACPA-negative patients (gray columns) in the H2-infused group and 8 in
the placebo group. Error bars represent the mean± standard deviation.3.2. Improvement in disease activity
Regarding thepatientswith RA, themean improvements inDAS28 in
the H2 and placebo groups are shown in Fig. 1a. In the 12 H2-infused pa-
tients, DAS28 decreased from 5.18 ± 1.16 to 4.02 ± 1.25 immediately
post-infusion and to 3.74 ± 1.22 after 4 weeks. A good DAS28 response
was observed in 7 patients, and a moderate response was observed in
4 patients. Although 1 patient showed no response, the scores of all
12 patients decreased at each measurement period. However, DAS28
was not reduced in the 12 patients of placebo group. Eleven patients
showed no DAS28 response, and 1 patient had a moderate response.
In 4weeks, theH2 group showed signiﬁcant improvement in disease ac-
tivity compared with the placebo group (p b 0.01).
A correlation between reduction in DAS28 by H2 treatment and
ACPAwas observed. Six patients in the H2-infused group and 4 patients
in the placebo group had increased ACPA levels (189 ± 164 μ/ml and
92.5 ± 106 μ/ml, respectively). However, 6 patients in the H2 group
and 8 patients in the placebo group showed no increase in ACPA levels.
To compare the therapeutic effects of H2 between the ACPA-negative
and ACPA-positive patients, improvements in DAS28 were presented
as the difference in DAS28 scores from baseline, as shown in Fig. 1b.Table 2
Demographic data for RA patients at baseline.
Placebo (n = 10) H2 (n = 10)
Age 68.2 ± 12.6 62.4 ± 18.4
Sex M, 2; F, 10 M, 2; F, 10
Duration of disease 4 years 3 months 4 years 11 months
DAS28 5.18 ± 1.16 5.10 ± 0.96
Data for age and DAS28 are presented as the mean ± standard deviation.Immediate post-infusion, DAS28 reduced signiﬁcantly in ACPA-
negative patients (p b 0.01). In 4weeks after baseline, it was signiﬁcant-
ly reduced in H2 group compared to the placebo group, bothwith ACPA-
positive patients (pb 0.05) andwithACPA-negative patients (p b 0.01).
The degree of the decrease inDAS28 in theH2 groupwas larger in ACPA-
negative patients than in ACPA-positive patients, immediately post-
infusion (p b 0.05) and in 4 weeks after baseline (p b 0.05).3.3. Effect of H2-saline infusion on TNFα, IL-6, MMP3, CRP, and urinary
8-OHdG
To investigate whether the antioxidant properties of H2 affected
serum levels of mediators in the ROS-mediated inﬂammatory chain,
which regulates and promotes the production of pro-inﬂammatory cy-
tokines, TNFα and IL-6 levels were measured. IL-6 was measured in
the serum from 9 patients in each group, and TNFα was measured in
the serum from 11 patients in the H2 group and 12 patients in the pla-
cebo group. Serum IL-6 at baseline was in the range of 0.24–372
(56.4 ± 120 pg/ml) in the H2 group and between 6.31 and 456
(90.3 ± 158 pg/ml) in the placebo group. As shown in Fig. 2, in the H2
group, the relative ratio of IL-6 in 4 weeks to baseline was signiﬁcantly
lower (p b 0.05) compared to the ratio in the placebo group. Serum
TNFα at baseline was ranged from 8.55 to 366 (55.6 ± 99.9 pg/ml) in
the H2 group and from 7.79 to 2550 (233 ± 730 pg/ml) in the placebo
group; however, there was no remarkable change in the relative ratio
of TNFα in 4 weeks to baseline between the H2 group and the placebo
Fig. 2. a. The relative ratios of levels of interleukin-6 (IL-6) and tumor necrosis factor-α
(TNFα) in 4 weeks to baseline in the H2 group (gray columns) and placebo group (open
columns) are represented. Error bars represent the mean ± standard deviation (closed
bars: H2 group; open bars: placebo group). Two samples in the H2 group and 3 samples
in the placebo group at baseline were below the level of the detection limit for IL-6
(b0.05 pg/ml) and were not added to the data. The serum sample for both cytokines in
4 weeks was not collected from 1 patient in the H2 group because the patient declined
collection of blood for the analysis of cytokine levels due to a fragile vein. b. Urinary 8-
hydroxydeoxyguanine (8-OHdG), which ranged from 5.2 to 25.6 ng/mg Cr, is represented
as relative ratios (×102%) between immediate post-infusion or in 4 weeks and the
concentration at baseline (closed circles: H2 group; closed triangles: placebo group).
Error bars represent the mean and standard deviation (SD).
Fig. 3. a. Matrix metalloproteinase-3 (MMP3) levels ranged from 31.3 ng/ml to 2054 ng/ml
and are represented as the relative ratios of the concentration in the serum (ng/ml) immedi-
ately post-infusion or in 4 weeks to the concentration at baseline (closed circles: H2 group;
closed triangles: placebo group). Error bars represent the mean ± standard deviation.
b. The relative ratio (×102%) of the concentration of C-reactive protein (CRP) immediately
post-infusion or in 4 weeks to the baseline concentration (closed circles: H2 group; closed
triangles: placebo group). Error bars represent the mean ± standard deviation.
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infusion and in 4 weeks from baseline are presented in Fig. 2b. Urinary
8-OHdG was signiﬁcantly decreased in the H2-infused group compared
to placebo group at only 4 weeks post-infusion.
As shown in Fig. 3a, levels of MMP3, which is thought to be an im-
portant marker of joint destruction in RA, were measured at baseline
(H2 group: range, 28.4 to 287 ng/ml; mean 106 ± 91.2 ng/ml; placebo
group: range, 31.3 to 2,054 ng/ml; mean 280±566 ng/ml), immediate-
ly post-infusion and in 4weeks. The relative ratio betweenMMP3 levels
immediately post-infusion and at baseline decreased by 21.1 ±19.5% in
the H2 group and by 6.3% ± 16.0% in the placebo group (p =0.0553). In
4 weeks after baseline, the relative ratio decreased by 19.2% ± 24.6% in
the H2 group and increased by 16.9% ± 50.2% in the placebo group,
thereby demonstrating the signiﬁcant anti-inﬂammatory potential of H2
(p b 0.05). In the H2 group, the serum concentration of CRP (mg/dl)
also decreased from 1.47 ± 1.77 at baseline to 1.13 ± 1.39 immediately
post-infusion and to 0.83 ± 1.29 in 4 weeks; however, in the placebo
group, CRP levels increased from 1.30 ± 2.00 at baseline to 1.41 ± 2.50
immediately post-infusion and to 1.60 ± 2.87 in 4 weeks. As shown in
Fig. 3b, the ratio of CRP levels in 4 weeks to baseline decreased in the H2
group while it increased in the placebo group (p = 0.05). The decreasein CRP by the infusion of H2 saline is consistent with the decline in
MMP3 levels observed at the end of the study.
4. Discussion
In the present study, a 5-day infusion of H2-enriched saline im-
proved disease activity in RA patients more effectively in 4 weeks than
immediately post-infusion, as conﬁrmed by the reduction of MMP3
levels. This indicates that the therapeutic potential of H2 administered
intravenously is observedwith a delay of 3 weeks. This ﬁnding is consis-
tent with our previous study, in which patients drank 500 ml of water
containing 4–5 ppm H2 daily for 4 weeks and RA disease activity was
signiﬁcantly improved. H2 seems to have a constitutive efﬁcacy, even
during the 4-week washout period when the patients did not drink H2
water. This effect cannot be explained by the continuous elimination
of hydroxyl radicals. In the present study, urinary 8-OHdG levels were
reduced after the delay of the washout period. Based on these 2 studies,
the mechanisms by which H2 reduces RA-induced inﬂammation seem
to be related not only to direct scavenging of hydroxyl radicals but
also to another indirect process related to autoimmune responses.
One such indirect mechanism of action is thought to be through
NF-κB modulation. As depicted in Fig. 4, the inﬂammation-related pos-
itive feedback loops are attributed to NF-κB action and are induced by
redox imbalance [5]. Therefore, excess ROS and NF-κB, which are locat-
ed at the center of the feedback loops, up-regulate pro-inﬂammatory
cytokines, including TNFα and IL-6, thereby activating nicotinamide
adenine dinucleotide phosphate oxidase (Nox), which overproduces
superoxide andH2O2 and creates Loop 3 as shown in Fig. 4. In particular,
hydroxyl radicals seem to be in excess because of the absence of distinct
biological scavengers. In the present study, H2 seems to have disrupted
this positive feedback loop by scavenging hydroxyl radicals. Levels of
Fig. 4.A schematic representation of the 3 loops involved in ampliﬁcation of inﬂammation
in patients with rheumatoid arthritis. Loop 1 depicts the nuclear factor (NF)-κB-tumor
necrosis factor-α (TNFα) positive feedback loop. Loop 2 depicts the redox sensing loop in-
volving reactive oxygen species (ROS)-NF-κB-interleukin-6 (IL-6) and/or TNFα. In the
present study, only Loop 2, which scavenges hydroxyl radicals directly or via NF-κB path-
ways, seemed to be blocked by H2 treatment. ROS,which are generated by theNox system
and are ampliﬁed through these loops, then stimulate synovial ﬁbroblasts, neutrophils,
and macrophages that promote cartilage and bone erosion via matrix metalloproteinase
(MMP)-3 or RANKL expression. In addition, the proteins modiﬁed by ROS may generate
a Loop 3, which may promote an autoimmune response by feeding back into Loops 1
and 2.
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reduced 4 weeks after the infusion of H2, thereby corroborating the im-
provement in DAS28. On the other hand, another important cytokine,
TNFα, which is also involved in the positive feedback loop, did not de-
crease. The mechanisms through which these 2 key cytokines partici-
pate in the pathogenesis of RA are different and often clinically
complement each other [22]. Within the scope of the present study,
H2 may ameliorate disease activity through reducing IL-6-mediated in-
ﬂammatory responses (see Loop 2 in Fig. 4). Although the transcription
of IL-6 is under the inﬂuence of NF-κB, theremay be anunknownmech-
anism which links IL-6 directly with oxidative stress or H2 itself. It
should be noted that the absence of TNFα reduction is also inconsistent
with a previous study of experimental animal models in which H2 was
used as an anti-inﬂammatory electron donor, and TNFα was down-
regulated [9,23]. As it was reported with RA patients for whom MTX,
the anchor drug for RA, was therapeutically effective [24], IL-6 may be
more responsible for disease susceptibility than TNFα. However, the
lack of inﬂuence of H2 on TNFα may be explained by the duration of
the study period, as the effect of H2 on TNFα levels may have been
missed. In addition, it should be noted that the disease duration of
most patients in the present study was quite long (4 years and
7 months on average); therefore, the T cells responsible for the chronic-
ity of RAwere likelywell established, and the disease durationmay thus
have inﬂuenced the effect of H2 on TNFα. It iswell-known that there are
important windows of opportunity for establishing therapeutic efﬁcacyof TNFα inhibitors and conventionalDMARDs [25]. It should benoted that
the number of patients in this study is very small, and the outcome to be
concluded is limited. Thus, in order to investigate themechanismof action
of H2, large-scale clinical investigations of early RA patients are necessary.
The prognosis and therapeutic responses in RA are inﬂuenced by the
presence of ACPA [1,26,27]. In the present study, we also observed a
correlation between therapeutic efﬁcacy of infused H2 and ACPA. The in-
fusion of H2was less effective in the ACPA-positive patients. However, the
total dose of H2 and the treatment periodwas restricted here. It is impor-
tant to investigate the efﬁcacy of infused H2 withmore frequent and lon-
ger treatments. In addition, the change in the value of ACPA after
treatment with infused H2 should be observed over a longer period.
It is currently difﬁcult to identify the difference between passive dif-
fusion of H2 from the stomach and the diffusion of H2 from circulating
venous ﬂow. However, in the present study, all patients who were ad-
ministered H2-saline exhibited a decrease in DAS28 on days 6–8; the
amount of H2 molecules infused was below 0.5 mg a day, which is less
than the amount of H2 in high H2 water (N2 mg). Although the total
amount of H2 administered during the 5-day treatment was less than
2.5 mg, the inﬂuence of infused H2-saline on improving inﬂammation
was comparable to that observed with high H2 water (total 56 mg
over 4 weeks). The absence of the signiﬁcant decrease of the urinary
8-OHdG immediately post-infusion may be due to the small amount
of H2 taken in the venous ﬂow, although it seems to be sufﬁcient to
disrupt the ROS-cytokine ampliﬁcation circle shown in Fig. 4. However,
further study is necessary to evaluate the additional beneﬁts of this
administration method.
The reason why such a small amount of H2 has proven effective in
patients with active RA may be explained by circulating blood ﬂow. It
is well-known that the whole blood (approximately 5–6 l) makes a
round of the circulatory system in approximately 1 min in an adult
weighing 50 kg. In the present study, 500 ml of H2-saline was drop
infused for 40 min. This indicates that even though the concentration
of H2 in the venous ﬂow was quite low [28], the circulating immune
cells, including lymphocytes, neutrophils, monocytes, and macro-
phages, which are responsible for the chronic inﬂammation of the
synovium, are circulated and exposed to at least 40 times the highest
concentration of H2 in the venous ﬂow during treatment. While it is
still unclear how many H2 molecules were absorbed in the activated
synovium in the inﬂamed joints, the inﬂuences observed in the present
study are thought to be due to the anti-inﬂammatory action of H2 mol-
ecules on the circulating immune cells. This hypothesis may explain the
therapeutic efﬁcacy of the infused H2, in spite of the absence of
decreased 8-OHdG levels immediately post-infusion, which is thought
to reﬂect the decrease in oxidative stress in the whole body. The signif-
icant reduction in urinary 8-OHdG levels in 4 weeks post-infusion may
represent the improvement of the disease condition, which could cause
an overall decrease in oxidative stress.
While Galen in ancientGreeceﬁrst described the physiopathology of
RA [29], effective RA therapy has emerged only recently. Glucocorticoid
steroid hormone, whichwas ﬁrst used for RA byHench in 1949, is prob-
ably the ﬁrst drug that dramatically improved the symptoms of RA [30].
However, it has been shown that glucocorticoids do not terminate the
progression of RA, nor cure the disease. Beginning in the 1970s,
DMARDs, including gold salts, were used for the early aggressive treat-
ment of RA. Among the many DMARDs developed since then, low dose
MTX, which was developed in the 1980s, has become an anchor drug
used to control the disease activity of RA [31–33]. More recently, mono-
clonal anti-TNFα antibodies emerged in the 1990s as a potential RA
therapy [34], and since then, the IL-6 inhibitor, tocilizumab, was
approved in 2008 in Japan [3]. These progresses made a so-called para-
digm shift, and disease remission has been achieved; however, it is still
difﬁcult to make patients completely drug-free and completely cure the
disease [1]. One of the difﬁculties is that almost all of these therapies are
based on immune-suppressive strategies and do not directly address
the currently unknown disease origin. The application of H2 described
473T. Ishibashi et al. / International Immunopharmacology 21 (2014) 468–473here is quite different from those conventional immunosuppressive
approaches. The anti-inﬂammatory properties of H2 are thought to be
based on the elimination of surplus, toxic free-radicals, including hy-
droxyl radicals and peroxynitrite. Therefore, the improvement in the
disease activity of RA observed in this study seems to suggest that the
pathophysiological disorder and the vicious circle of inﬂammation in
RA are in part caused by excess radicals. These non-speciﬁc but effective
anti-inﬂammatory capabilities of H2 can affect undesired inﬂammation
inherent in other diseases, including atherosclerosis,which also exhibits
ROS-related inﬂammation pathways [5]. As the safety of H2 has been
established, it is possible to consider daily intake of H2 [10,16]. This
may alter the morbidity risk as well as the natural course of RA and re-
lated diseases. However, more intensive studies including a wide range
of RApatients are necessary, not only to establish the bestway ofmono-
therapy using H2, including the combination of drinking high H2 water
and venous infusion of H2, but also to develop combination therapies
with conventional DMARDs, biological agents, or glucocorticoids. Fur-
thermore, the efforts to investigate the unknown bioactivities of H2
should be continued, as there remain unexplainable factors in the ther-
apeutic efﬁcacy of H2 [5,10].
In conclusion, we have demonstrated that intravenous infusion of H2
is effective in treating RA. This method could be useful not only for con-
trolling RA but also for preventing age-related inﬂammatory diseases.
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